Pneumonia · adults receiving EN via nasogastric or gastrostomy tube
It is very uncertain whether higher threshold (500 mL per six hours or greater) changes pneumonia (until discontinued or up to 28 days) compared with lower threshold (less than 500 mL per six hours) at time of aspiration (very low certainty).
1 finding from 1 review
Length of hospital stay · adults receiving EN via nasogastric or gastrostomy tube
1 finding from 1 review
Abdominal pain frequency or change in frequency · people with Crohn's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Abdominal pain intensity or change in intensity · people with Crohn's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Withdrawals due to adverse events · people with Crohn's disease
1 finding from 1 review
Treatment success as defined by the authors · people with Crohn's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of participants developing a new pressure ulcer · pressure ulcer prevention
Alternating pressure (active) air surfaces on operating tables and… may leads to lower proportion of participants developing a new pressure ulcer compared with reactive gel surfaces on operating tables followed by foam surfaces… (low certainty).
1 finding from 1 review
Time to pressure ulcer development · pressure ulcer prevention
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Support surface associated patient comfort · pressure ulcer prevention
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All reported adverse events · pressure ulcer prevention
1 finding from 1 review
Health‐related quality of life · pressure ulcer prevention
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Cost‐effectiveness · pressure ulcer prevention
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality · ambulatory patients with multiple myeloma receiving immunomodulatory agents
It is very uncertain whether aspirin (ASA) changes all‐cause mortality compared with vitamin K antagonist (VKA) (very low certainty).
1 finding from 1 review
All‐cause mortality · ambulatory patients with multiple myeloma receiving immunomodulatory agents
It is very uncertain whether aspirin (ASA) changes all‐cause mortality compared with low molecular weight heparin (LMWH) (very low certainty).
2 findings from 1 review
Symptomatic DVT · ambulatory patients with multiple myeloma receiving immunomodulatory agents
It is very uncertain whether aspirin (ASA) changes symptomatic deep vein thrombosis compared with low molecular weight heparin (LMWH) (very low certainty).
2 findings from 1 review
Pulmonary embolism · ambulatory patients with multiple myeloma receiving immunomodulatory agents
It is very uncertain whether aspirin (ASA) changes pulmonary embolism compared with low molecular weight heparin (LMWH) (very low certainty).
2 findings from 1 review
Major bleeding · ambulatory patients with multiple myeloma receiving immunomodulatory agents
It is very uncertain whether aspirin (ASA) changes major bleeding compared with low molecular weight heparin (LMWH) (very low certainty).
2 findings from 1 review
Minor bleeding · ambulatory patients with multiple myeloma receiving immunomodulatory agents
It is very uncertain whether aspirin (ASA) changes minor bleeding compared with low molecular weight heparin (LMWH) (very low certainty).
1 finding from 1 review
Symptomatic DVT · ambulatory patients with multiple myeloma receiving immunomodulatory agents
It is very uncertain whether aspirin (ASA) changes symptomatic deep vein thrombosis compared with vitamin K antagonist (VKA) (very low certainty).
1 finding from 1 review
Minor bleeding ‐ not reported · ambulatory patients with multiple myeloma receiving immunomodulatory agents
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found